Cart
sales@molnova.com
Debrisoquin hydriodide
CAS No. 1052540-65-4
Debrisoquin hydriodide( 1,2,3,4-tetrahydroisoquinoline-2-carboximidamide hydroiodide )
Catalog No. M28374 CAS No. 1052540-65-4
Debrisoquin hydriodide is a chemical compound.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 34 | In Stock |
|
| 25MG | 56 | In Stock |
|
| 50MG | 87 | In Stock |
|
| 100MG | 132 | In Stock |
|
| 200MG | 194 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDebrisoquin hydriodide
-
NoteResearch use only, not for human use.
-
Brief DescriptionDebrisoquin hydriodide is a chemical compound.
-
DescriptionDebrisoquin hydriodide is a chemical compound.
-
In Vitro——
-
In Vivo——
-
Synonyms1,2,3,4-tetrahydroisoquinoline-2-carboximidamide hydroiodide
-
PathwayOthers
-
TargetOther Targets
-
RecptorAMPK|TNF-α|ROS|ABCB1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1052540-65-4
-
Formula Weight303.147
-
Molecular FormulaC10H14IN3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESI.NC(=N)N1CCc2ccccc2C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hsiao SH, et al. Hernandezine, a Bisbenzylisoquinoline Alkaloid with Selective Inhibitory Activity against Multidrug-Resistance-Linked ATP-Binding Cassette Drug Transporter ABCB1. J Nat Prod. 2016 Aug 26;79(8):2135-42.
molnova catalog
related products
-
SR9238
SR9238 is a synthetic agonist of liver X receptor inverse (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively).
-
Nadifloxacin
Nadifloxacin(OPC7251) is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris.
-
RMC-6291
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
